Avid Bioservices (CDMO) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Avid Bioservices (CDMO) PT Raised to $6 at H.C. Wainwright
July 17, 2018 10:22 AM EDTH.C. Wainwright raised its price target on Avid Bioservices (NASDAQ: CDMO) to $6.00 (from $5.00) while maintaining a Buy rating.
Analyst Joseph Pantginis commented, "Yesterday, CDMO reported F4Q18 and FY18 ended April 30, 2018, posting EPS of $0.03 and ($0.56), respectively, compared with our estimate of ($0.23) and ($0.87) and consensus of ($0.15) and... More
